Why is early engagement with EMA, payers, KOLs, and patient groups so important?

Access decades of experience

Strategic Stakeholder Engagement Timeline

When and how to connect with EMA, payers, KOLs, and patient groups throughout your development journey.

Regulatory Scientific Advice Process

How EMA and national Health Agency consultations work and what guidance you can expect at each development stage.

European Payer Landscape Navigation

Understanding HTA bodies like NICE, HAS, and G-BA, plus new parallel consultation opportunities with EMA.

Risk Mitigation Through Early Planning

Real scenarios showing how proactive engagement prevents costly late-stage program changes and market access barriers.